BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29226763)

  • 1. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
    Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
    J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].
    Yan X; Li B; Qin TJ; Qu SQ; Pan LJ; Wu JY; Liu D; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):15-20. PubMed ID: 33677863
    [No Abstract]   [Full Text] [Related]  

  • 3. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
    Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
    Tefferi A; Guglielmelli P; Nicolosi M; Mannelli F; Mudireddy M; Bartalucci N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Begna KH; Naseema Gangat ; Pardanani A; Vannucchi AM
    Leukemia; 2018 Jul; 32(7):1631-1642. PubMed ID: 29654267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
    Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
    Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
    J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelofibrosis Treatment Algorithm 2018.
    Tefferi A; Guglielmelli P; Pardanani A; Vannucchi AM
    Blood Cancer J; 2018 Jul; 8(8):72. PubMed ID: 30065290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
    Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
    Jawhar M; Schwaab J; Álvarez-Twose I; Shoumariyeh K; Naumann N; Lübke J; Perkins C; Muñoz-González JI; Meggendorfer M; Kennedy V; Metzgeroth G; Fabarius A; Pfeifer D; Sotlar K; Horny HP; von Bubnoff N; Haferlach T; Cross NCP; Hofmann WK; Sperr WR; García-Montero AC; Valent P; Gotlib J; Orfao A; Reiter A
    J Clin Oncol; 2019 Nov; 37(31):2846-2856. PubMed ID: 31509472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
    Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
    Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
    Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
    Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
    Guglielmelli P; Lasho TL; Rotunno G; Score J; Mannarelli C; Pancrazzi A; Biamonte F; Pardanani A; Zoi K; Reiter A; Duncombe A; Fanelli T; Pietra D; Rumi E; Finke C; Gangat N; Ketterling RP; Knudson RA; Hanson CA; Bosi A; Pereira A; Manfredini R; Cervantes F; Barosi G; Cazzola M; Cross NC; Vannucchi AM; Tefferi A
    Leukemia; 2014 Sep; 28(9):1804-10. PubMed ID: 24549259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.